ECM-focused Advantage Nanofiber Solutions offers electrospun nanofiber substrates that mimic extracellular matrix (ECM), addressing a key limitation of traditional TCPS. This positions the company to target biotech and pharma players aiming to improve preclinical drug screening and cell culture models to increase translational success.

Clinical Translation Gap The stated issue of >99% failure for drugs developed on TCPS creates a compelling sales angle: prospect customers in R&D and translational science need more physiologically relevant substrates to de-risk pipelines and align in vitro results with in vivo outcomes.

Pilot-to-Scale Path The ability to operate in standard multiwell plates or scale configurations offers a clear upsell path from small-scale assays to larger culture systems, appealing to contract research organizations (CROs) and pharma partners seeking flexible, scalable solutions.

Low Resource Footprint With a lean team and revenue in the lower mid-range, there is an opportunity to engage smaller biotech startups and academic labs that require cost-effective, high-value substrates without heavy procurement cycles.

Tech-Enabled Sales Adoption can be accelerated by leveraging existing tech stack signals (Google Cloud, e-commerce integrations) to streamline ordering, trials, and post-sale support, while highlighting the product’s potential to integrate with standard lab workflows and data capture.